MetAlert Inc. (MLRT) Announces Canadian Distributor Launch of Award-Winning 4G GPS SmartSole Medical Monitoring Device for Alzheimer’s, Dementia, and Autism

• ARPA-H is investing a billion dollars to encourage cutting-edge research for Alzheimer’s, supporting bold ideas to pursue and drive new biomedical breakthroughs
• The Department of Health and Human Services is investing in research and technology to help keep Alzheimer’s patients in their homes longer, train caregivers to support them, and educate Americans about Alzheimer’s early warning signs – all of which MetAlert provides products and solutions for
• The Alzheimer’s Disease diagnostic and therapeutic market is expected to reach an estimated $9.6 billion by 2027

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, has announced that Canadian distributor Red Dot Alerts has launched the new award-winning 4G GPS SmartSole – a wearable medical monitoring device integrated into the orthotic insole allowing for discreet tracking and remote monitoring for those with Alzheimer’s, dementia, and autism (https://ibn.fm/NSPZ4).

The launch is supported by a marketing and advertising campaign, including radio ads, magazine ads, and mailers to medical clinics, hospitals, pharmacies, and senior residence facilities across Canada. The advertising campaign will continue into Spring 2023, coinciding with Canada’s Fall Prevention Month in November and Alzheimer’s Awareness Month in January.

The U.S. administration proclaimed November as National Alzheimer’s Awareness Month and the administration has launched the Advanced Research Projects Agency for Health (ARPA-H). ARPA-H is investing a billion dollars in cutting-edge research for Alzheimer’s, in support of new biomedical breakthroughs. The Department of Health and Human Services is investing in research and technology to help keep Alzheimer’s patients in their homes longer, train caregivers to support them, and educate Americans about Alzheimer’s early warning signs.

MetAlert provides products and solutions for all of these issues, supporting both the caregivers and family members of millions of people who have been diagnosed with Alzheimer’s Disease.

“Insurance or government financial assistance is a key component in helping families address the costs associated with caring for someone with Alzheimer’s or dementia. Qualifying GPS SmartSole customers can receive assistance from Medicaid programs using our National Provider Identifier (“NPI”): 1447709290,” MetAlert CEO Patrick Bertagna said. “And similar reimbursement programs have been initiated for the GPS SmartSole in other countries such as Canada, the U.K., and Norway, so we are very excited to hear about additional funding becoming available through this new ARPA-H program the administration has launched with a billion-dollar commitment.”

The Alzheimer’s Disease diagnostic and therapeutic market was valued at $6.9 billion in 2021 and is expected to grow at a CAGR of 5.51% during the forecast period, resulting in an estimated value of $9.6 billion by 2027. Driving factors for the market’s growth include the increased use of biomarkers in Alzheimer’s diagnosis and drug development and the rising prevalence of Alzheimer’s Disease worldwide (https://ibn.fm/cMEMO).

“We are thrilled to offer the GPS SmartSole to Canadians. This innovative insole could be lifesaving for anyone who tends to wander, like seniors with dementia and children with autism,” Red Dot Alerts Director of Business Operations Roxanne Ayotte said. “With a click of the app, caregivers can rest easy knowing where their loved ones are. It’s truly a game-changer.”

With over 20 years of experience and an extensive patent portfolio, MetAlert is a solution leader for consumers and patients who have Alzheimer’s, dementia, and autism – a growing market that already represents approximately 2.9% of the world’s population. Many of these consumers are dealing with patients that have a problem with memory but have the adversity to wearing unknown items, making traditional tracking products impractical.

MetAlert and its subsidiaries are engaged in designing, developing, manufacturing, distributing, and selling products and services in GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring. The company offers a global end-to-end hardware, software, and connectivity solution, in addition to developing two-way tracking technologies, which seamlessly integrate with consumer products and enterprise applications.

For more information, visit the company’s website at www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.